Chaitra Ashok Badve MD, MBBS, Presenter: Nothing to Disclose

Alice Yu BS, MS, Abstract Co-Author: Nothing to Disclose

Dan Ma MS, Abstract Co-Author: Nothing to Disclose

Anagha Deshmane, Abstract Co-Author: Nothing to Disclose

Yun Jiang, Abstract Co-Author: Nothing to Disclose

Andrew Sloan, Abstract Co-Author: Nothing to Disclose

Jeffrey Lloyd Sunshine MD, PhD, Abstract Co-Author: Research support, Siemens AG Travel support, Siemens AG Travel support, Koninklijke Philips NV Travel support, Sectra AB Travel support, Allscripts Healthcare Solutions, Inc

Vikas Gulani MD, PhD, Abstract Co-Author: Research support, Siemens AG

Mark A. Griswold PhD, Abstract Co-Author: Research support, Siemens AG Royalties, Siemens AG Royalties, General Electric Company Royalties, Bruker Corporation Contract, Siemens AG

Magnetic Resonance Fingerprinting (MRF) is a novel framework for simultaneous accurate quantitation of multiple MR tissue properties. Here we apply MRF for evaluation of different types of intra-axial brain tumors.

14 patients including 7 glioblastoma multiforme (GBM), 4 oligodendrogliomas (OG) and 3 metastases (METS) were scanned using a MRF protocol. Imaging was acquired through representative areas of brain and quantitative T1 and T2 maps were generated. T1 and T2 quantification of solid tumor component, immediate perilesional white matter (PWM) within 1 cm from enhancing margin, and contralateral white matter (CWM) was performed using ROI analysis. Student's t-test was used for statistical analysis.

Mean T1, T2 of solid parenchyma in GBMs (n = 7) were 1786 ± 243 ms; 131 ± 30 ms, respectively. T1, T2 of abnormal signal within 1cm of enhancing margin in GBMs (n =7) were 1704 ± 471 ms; 130 ± 47 ms. T1, T2 for solid parenchyma in METS were 1243 ± 132 ms; 104 ± 31 ms. Measurements were in agreement with published literature. Tumor T1, T2 were different than T1, T2 of CWM (n=14, p < 3.8 x 10-7, p < 2.4 x 10-7). There was difference between T1, T2 of PWM of GBMs and METS from their CWM (n=10, p<0.0002, p<0.0001). There was difference between the T1 of solid regions of GBMs and METS (T1: p < 0.01). Also, there was difference between the PWM of GBMs and METS (T1: p < 0.03; T2: p < 0.07). T2 relaxometry revealed difference between GBMs and OGs (p < 0.04).  

MRF is able to simultaneously measure T1 and T2 values of brain tumors and surrounding tissues. It can distinguish with high statistical significance between tumor types and PWM changes from CWM. Preliminary data supports using MRF to identify regions of infiltrative edema in GBM, and differentiation of tumor types and grades.

The preliminary data on MRF of brain tumors suggest application of this technique to identify, diagnose, and offer prognosis of intracranial masses, delineation of tumor margins, and characterization of therapeutic response.

Badve, C, Yu, A, Ma, D, Deshmane, A, Jiang, Y, Sloan, A, Sunshine, J, Gulani, V, Griswold, M, Magnetic Resonance Fingerprinting of Brain Tumors: Initial Clinical Results.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14018625.html